Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.

Takeda has touted the potential of the company’s Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.

Genetically modified mosquitoes were released for the first time in the United States, taking flight in the Florida Keys in a pilot program intended to reduce the spread of deadly diseases such as dengue, yellow fever and the Zika virus.

A new study that analyzed the coronavirus outbreak in Brazil found a link between the spread of the virus and past outbreaks of dengue fever that suggests exposure to the mosquito-transmitted illness may provide some level of immunity against Covid-19.

Takeda Pharmaceutical Co.’s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but TAK-003 failed to protect against one type of the virus in people with no prior exposure to dengue.